Drugs / XP-102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05275374 | Dec 2025 → Dec 2027 expected | colorectal cancer, melanoma, non-small cell lung carcinoma, thyroid cancer | Xynomic Pharmaceuticals, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XP-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05275374 ↗ |
| Known as | BI 882370 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4212692 ↗ |
| Modality | Small molecule | — CHEMBL4212692 ↗ |
| Route | Oral | “administered orally” NCT05275374 ↗ |